New efficacy and safety data adds to evidence suppoith afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients
"The new sub-analysis confirms the consistent safety profile of afatinib…
27 October 2013 | By Boehringer Ingelheim
"The new sub-analysis confirms the consistent safety profile of afatinib in Asian patients..."